Abstract
Introduction
Diabetes mellitus (DM) is a metabolic disorder identified by hyperglycemia and consists of several types. Of which, type 2 DM (T2DM) could occur due to insulin resistance (IR) and obesity. 1 Whereas, prediabetes (pre-DM) is a state where glucose levels are elevated but individuals are neither DM patients nor normal healthy individuals. 2 Closely related to DM is metabolic syndrome (MetS) which is a cluster of risk factors caused mainly by IR and abdominal obesity, leading to precipitating risk of cardiovascular diseases (CVD), stroke and diabetes. 2, 3 Thus IR and hyperinsulinemia are hallmarks of the metabolic syndrome. 4 The hyperinsulinemic/euglycemic clamp has recently emerged as the gold standard method to detect IR, though clinically impractical to do so. Subsequently a surrogate marker for IR is needed. Recently, several studies have reported that the lipid ratios triglyceride (TG)/high-density lipoprotein (HDL)-C, total cholesterol (TC)/HDL-C, and low-density lipoprotein (LDL)-C/HDL-C are surrogate marker of IR. 5 Coupled with hyperglycemia is glycation. Glycation is a normal nonenzymatic reaction between reducing sugars and proteins, lipids or nucleic acids, however unfavorable. 6 Resulting from glycation are products called circulating advanced glycation end-products which bind to lipoproteins and delay their clearance. 7 Hyperglycemia increases the formation of oxidized and glycated LDL-C (GLDL-C), which are important modulators of atherosclerosis and CVD. 8 T2DM features important modification of both LDL-C and HDL-C. 9 Plasma levels of HDL-C are decreased during T2DM due to increased catabolism of HDL-C particles. Furthermore, qualitative abnormalities of HDL-C are described; such as significant reduction in their antioxidative and endothelium-dependent vasorelaxant properties. 10 TGs are also affected in T2DM. Hypertriglyceridemia produces atherogenic, small, dense forms of LDL-C and decreases cholesterol transport to the liver by HDL-C. Therefore, high value of the TG/HDL-C ratio in the present work can enable identification of diabetic patients at a higher risk of CVD. 11 Other emerging indices are hematological indices, such as mean platelet volume (MPV), platelet (PLT) count and white blood cell subtypes. They are among the inflammatory markers that are considered as reliable prognostic indicators for diabetes complications. 12, 13 In addition, atherogenic index of plasma (AIP; log TG/HDL-C) has lately been considered as a surrogate estimate of the atherogenicity dyslipidemia among T2DM patients. 14, 15 Also, adiposity markers such as conicity index (CI), body adiposity index (BAI) and waist-height ratio (WHtR) are investigated for the estimation of the risk of coronary heart diseases. 16, 17 Participants, materials and methods
Study participants
The study was conducted at The University of Jordan Hospital (UoJH) at the diabetes and endocrinology outpatient clinics. The candidates were divided into: healthy lean normoglycemic control group with 30 participants, 30 patients in a non-DM MetS group, and 30 patients in a pre-DM/ newly diagnosed T2DM MetS group. The study was approved by the scientific research committee at the School of Pharmacy at The University of Jordan and by the UoJH institutional review board. All potential candidates were approached and informed thoroughly about the study, with a written informed consent.
Anthropometric measurements
Weight and height were measured using a balance mounted stadiometer. Waist circumference (WC) was measured using a nonstretchable tape at the midpoint between the last rib and the upper iliac crest, and hip circumference (HC) was measured around the widest section of the buttocks. Body mass index (BMI) was calculated as body weight (kg) divided by the square of height (m²). WHR and WHtR were calculated by dividing the WC (cm) by HC (cm) and height respectively. CI and Body adiposity index (BAI) were calculated using the following formulae. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using a digital blood pressure meter. Table 2 shows the clinical characteristics of study participants. The mean age is significantly higher in the MetS pre-DM/T2DM group compared with the nondiabetic MetS and control group. The BMI, WC, HC and lipid profile were also significantly greater in both MetS groups. Mean FBG and HbA1c were significantly higher in the pre-DM/T2DM MetS group compared with the nondiabetic and control group. Table 2 shows the WHtR (p < 0.05), CI (p < 0.01) and BAI (p < 0.001) were higher in the MetS and MetS-pre/T2DM group when compared with controls. As for hematological indices, the PLR showed intergroup difference in nondiabetic MetS patients versus MetS-pre/T2DM with significance (p < 0.05) being higher in the MetSnondiabetic group. Whereas MPV in both MetS groups was higher than in controls.
Results

General and clinical characteristics
Comparisons of indices
TG/HDL-C and AIP had significant intergroup difference (p < 0.001) when compared between healthy participants and both MetS and MetSpre/T2DM. GHDL (mmol/l) and GLDL (mmol/l) lacked any statistically significant variations in nondiabetic MetS and MetS-pre/T2DM groups (p > 0.05; Table 3 ). Interestingly, when introducing the ratio of the means of GHDL-C/ HDL-C, there were highly significant intergroup differences (p < 0.001) when comparing both nondiabetic MetS and MetS-pre/T2DM groups versus the healthy control group (Table 3 and Figure 1 ). However, GLDL-C/LDL-C did not show the same behavior for both MetS groups versus controls ( Figure 2 ).
Metabolism-related biomarkers GHDL-C and GLDL-C
The glucolipotoxicity-related metabolism biomarkers GHDL (mmol/l) and GLDL (mmol/l) were observed as higher in MetS pre/T2DM when compared with normoglycemic lean controls. Interestingly, GHDL-C and GLDL-C plasma levels lacked any statistically significant variations. Table 3 displays the potential associations and p values between indices and biomarkers. Starting with adiposity indices, both GHDL-C and GLDL-C showed positive proportionality with WHR p < 0.05 only in nondiabetic MetS patients.
Correlation between indices and metabolic biomarkers
Notably GLDL-C in pre/diabetic MetS participants associated positively with BAI. Direct relationships were identified for whole population GLDL-CI pairs. In all study arms, CI had an inverse correlation with GHDL-C, but showed a positive correlation with GLDL-C only in controls. For hematological indices, only GLDL-C correlated directly with PLT count (p < 0.01). Both biomarkers correlated inversely (p < 0.05) with MPV in the control group. In the nondiabetic MetS group, GHDL-C correlated inversely with both monocyte count and MLR.
Finally, there are potential correlations between atherogenicity indices and metabolic biomarkers in each individual study arm. Collectively, the total population atherogenic indices showed potential significant correlations in comparison with each study arm, which lacked those correlations. As such, GHDL-C correlated positively and significantly with all indices; however, only GLDL-C significantly correlated with the TC/HDL-C ratio (p < 0.01). Interestingly, in the MetS-nondiabetic group GLDL-C inversely correlated with each index. Exceptionally, AIP of the pre/diabetic MetS group showed a similar inverse correlation.
Discussion
This study aimed to evaluate the intergroup discrepancies in plasma levels of those proteins in Table 1 . ELISA kit precision.
%CV GLDL-C Inter-assay <10%
Intra-assay <10%
GHDL-C Inter-assay <15%
Intra-assay <15%
CV, Coefficient Of Variation; GHDL, glycated high-density lipoprotein; GLDL, glycated low-density lipoprotein. Table 2 . Table 2 . AIP, atherogenic index of plasma; BAI, body adiposity index; BMI, body mass index (kg\m²); CI, conicity index; DBP, diastolic blood pressure (mmHg); DM, diabetes mellitus; FBG, fasting blood glucose (mg/ dl); GHDL-C, glycated high-density lipoprotein; GLDL-C, glycated low-density lipoprotein (mg/dl); HbA1c, hemoglobin A1c (%); HC, hip circumference (cm); HDL-C, high-density lipoprotein (mg/dl); LDL-C, low-density lipoprotein (mg/dl); MetS, metabolic syndrome; MLR, monocyte-to-lymphocyte ratio (×10^3/l); MPV, mean platelet volume (fl); NLR, neutrophil-to-lymphocyte ratio (×10^3/l); PLT, platelet count (×10^3/l); PLR, platelet-to-lymphocyte ratio; RDW, red blood cell distribution width (CV%); SBP, systolic blood pressure (mmHg); T2DM, type 2 diabetes mellitus; TC, total cholesterol (mg/dl); TG, triglycerides (mg/dl); WC, waist circumference (cm); WHR, waist-to-hip ratio; WHtR, waist to height ratio. Table 2 .
(Continued) Table 3 .
The intra-group correlations of the metabolic biomarkers with adiposity, hematologic and atherogenic indices. AIP, atherogenic index of plasma; BAI, body adiposity index; CI, conicity index; DM, diabetes mellitus; GHDL-C, glycated high-density lipoprotein; GLDL-C, glycated low-density lipoprotein; MetS, metabolic syndrome; MLR, monocyte-to-lymphocyte ratio; MPV, mean platelet volume; NLR, neutrophil-to-lymphocyte ratio; PLT, platelet; PLR, platelet-to-lymphocyte ratio; RDW, red blood cell distribution width; T2DM, type 2 diabetes mellitus; WHR, waist-to-hip ratio; WHtR, waist to height ratio. nondiabetic MetS patients as well as MetS-pre/ T2DM patients, and to examine the intra-group associations of those biomarkers with each other, with adiposity indices (WHR, WHtR, CI, and BAI), with hematological indices [red blood cell distribution width (RDW), MPV, neutrophil-tolymphocyte ratio (NLR), PLR, MLR] and with atherogenic indices (AIP, TC/HDL-C and LDL-C/ HDL-C ratios). Our goal was to provide a therapeutic evidence for using GLDL-C and GHDL-C as drug targets in treating metabolic disturbances like obesity, MetS and T2DM among the Middle Eastern populations. Their utility as surrogate molecular biomarkers for prediction/prevention of metabolic derangements is strongly suggested.
In line with the effect of glycation of lipoproteins such as GLDL-C and GHDL-C and their significant role in the pathophysiology of diabetes complications, 18 several studies have reported that dyslipidemia in T2DM individuals is very common, and this phenomenon is associated with a significantly increased risk of Coronary Artery Disease (CAD) relative to individuals without diabetes. 18, 19 The underlying mechanisms increase the normal residence time of LDL-C in plasma from 3 days to 5 days for highly atherogenic LDL-C. In addition, damage to apoB100 by glycation influences the residence time. 19, 20 However, reductions in the antioxidative and anti-inflammatory effects of HDL-C have been reported in patients with diabetes, alongside an impaired ability to counteract the inhibition of endothelium-dependent vasorelaxation by oxidized LDL-C. Moreover, glycation has recently been shown to reduce the sphingosine-1-phosphate content of HDL-C, reducing its ability to activate protective intracellular survival pathways GHDL-C, glycated high-density lipoprotein-cholesterol; GLDL-C, glycated low-density lipoprotein-cholesterol; HDL-C, highdensity lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; MetS, metabolic syndrome.
during oxidative stress, leading to further catabolism. 20 A study by Shen and colleagues, investigated whether apolipoprotein A (apoA)-I glycation and paraoxonase (PON) activities are associated with the severity of CAD in patients with T2DM. It is well established that the main function of PON 1 and PON 3 is to prevent LDL-C from peroxidation, conferring antagonistic effects against atherosclerosis. Strikingly ApoA-1 is responsible for reverse cholesterol transport, stabilization of atherosclerotic plaque, and anti-inflammatory and antioxidant effects. The results of the study demonstrated that the relative intensity of apoA-1 glycation was higher but the activities of HDL-C-associated PON1 and PON3 were lower in diabetic patients with significant CAD than in those without. 21 Experimentally, HDL-C can impede the glycative modification of LDL-C, and this property of HDL-C is more marked with HDL obtained from people with higher serum PON1 activity. A small amount of oxidation does accompany in vitro glycation, and the process is best regarded as glycoxidation. Lipid peroxidation of LDL-C accompanying in vitro glycation is impeded in the presence of HDL-C, and it is possible that adduction of lipid peroxidation products to the e amino groups of lysine residues of apoB in vivo renders these groups more susceptible to combinations with glucose. 22 In vivo, oxygen-free radical exposure of LDL-C may predispose to glycation and explain the high levels of circulating GLDL-C. HDL-C, by impeding LDL-C oxidation, may thus in turn slow its glycation. Another study by Galland and colleagues on T2DM, used the oxidized LDL-C/ LDL-C ratios, as an accurate estimation of in vivo LDL-C oxidation, which has been reported as elevated and associated with macrovascular disease. Lipid abnormalities play an important role in the development of atherosclerosis in T2DM. Thus, dyslipidemia observed in T2DM includes both quantitative and qualitative lipid abnormalities. Of the qualitative abnormalities is the glycation of apolipoproteins . 23 Based on Galland and colleagues' work we introduced in our study a highly novel ratio of glycated HDL-C (mmol/l)/ HDL-C (mmol/l) and glycated LDL-C (mmol/l)// LDL-C (mmol/l), for their unprecedented diagnostic/prognostic utility as glycation indices in MetS and T2DM.
In recent years, the PLR and NLR ratios were also introduced as new inflammatory markers in different situations. 24, 25 The PLR ratio combines the predictive risk of PLT and lymphocyte counts. 26 In Akdoğanand colleagues, HbA1c, which is a marker of long-term glycemic control, weakly correlated with MPV, Platelet Distribution Width (PDW), RDW, PLR, and NLR ratios and AIP (log10 TG/HDL-C). 27 There is an evidence that hyperglycemia induces nonenzymatic glycation of proteins on the surface of the platelets and erythrocytes which decreases membrane fluidity and increases its reactivity. 28 The link between hyperlipidemia and platelet hyperactivation is supported by the previous studies that lipid-lowering agents possess antithrombotic properties. 29 Adak and colleagues showed that hyperglycemiainduced oxidative stress leads to structural functional alterations in red blood cells. 30 In a recent study, Pérez 31 compared the general adiposity index (BMI) with abdominal obesity indices in order to examine the best predictor of cardiometabolic risk factors. The study concluded that all obesity indices correlated significantly with blood pressure, HDL-C, TC/HDL-C, LDL-C, TG, FBG and HbA1c. Nevertheless, our findings could identify significant correlations of WC and WHtR with both biomarkers (p < 0.001). This may suggestively conclude that both GLDL-C and GHDL-C can be considered as predictive biomarkers of deranged metabolic status and its consequences.
Our results are in accordance with previous studies conducted by Bavbek and colleagues and Ozder and Eker, which showed association of increased MPV with diabetes. 32, 33 Demirtas and colleagues also found that MPV and PLR ratios were significantly higher in diabetic patients than in the control group. 34 Moreover, MPV may be related to poor glycemic control, possibly due to the osmotic effect resulting from increased glucose levels and some of its metabolites in blood. 35 
Conclusion
Introducing the ratio of GHDL-C/HDL-C and GLDL-C/LDL-C as novel predictive indices of metabolic derangements alongside to adiposity, atherogenic and hematological indices may be of clinical relevance to metabolic anomalies. This is a cross-sectional study, thus, no causality relationship could be concluded. It cannot be precisely speculated whether the biomarker itself caused the metabolic disturbances of diabetes and MetS or the diabetes and MetS caused the level change of biomarker. Future prospective cohort studies are needed to establish a causeeffect relationship.
Author's Note
Approval for the study was obtained from Institutional Review Board (IRB) affiliated with the National Center for Diabetes, Endocrinology, and Genetics (1151, 1152, 1153/9/SM). Author confirms that all patients have provided their signed consent forms.
